市場調查報告書
商品編碼
850169

全球並用抗糖尿病藥物市場:成長,趨勢,預測

COMBINATION ANTI-DIABETES DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 90 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球並用抗糖尿病藥物市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介相關資訊彙整。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場趨勢

  • 市場概要
  • 促進要素
  • 阻礙要素
  • 波特五力分析

第5章 市場區隔

  • 各藥物
    • 並用藥
      • 胰島素並用藥
        • NovoMix
        • Ryzodeg
        • Xultophy
      • 口服並用藥
        • Janumet
  • 各地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲

第6章 市場指標

  • 第一型糖尿病人口
  • 第二型糖尿病人口

第7章 競爭環境

  • 企業簡介
    • Novo Nordisk
    • Merck
    • Sanofi

第8章 市場機會與未來趨勢

目錄
Product Code: 63845

The diabetes population in the world is increasing continuously. This trend is mainly due to the changing lifestyle of the majority of the population. Most of the population have unhealthy lifestyles. The change in lifestyle is due to the economic and industrial development in recent times in most of the countries. For most of the population, sedentary lifestyles and seemingly endless fast-food options have replaced the traditional ways of work, travel, and cuisine, making way for the increase of diseases, such as diabetic. WHO projects that diabetes will be the seventh leading cause of death in 2030. In 2014, 8.5% of adults aged 18 years and older had diabetes. In 2015, diabetes was the direct cause of 1.6 million deaths and in 2012, high blood glucose was the cause of another 2.2 million deaths. It expected that this number would keep increasing shortly.

Key Market Trends

Diabetes Patients Need More than One Drug to Control their Glycemic Level

  • Diabetes is considered to be a rich man disease, not only because of the cost of the drugs but also because of the number of medicines one must consume. Over the years, a large number of drug manufacturers has introduced combination drugs, thus making it more convenient for consumers.
  • These combination drugs have two or more active pharmaceutical ingredients, thus serving the purpose of two anti-diabetic drugs. The manufacturers have in the past started with essential oral medicines, such as Janumet and now have developed advanced insulin combinations, such as Ryzodeg and Xultophy.
  • Consumer preference for these drugs has increased considerably over time. The combination drugs market was valued 4.01 billion in 2018 and is expected to witness a CAGR of 10%, during the forecast period.

Ryzodeg is Expected to Record a CAGR of 23%

  • Ryzodeg is a combination of ultra-long-acting insulin degludec (basal) and rapid-acting prandial insulin aspart (bolus).
  • At present, consumers need to use both the basal and bolus insulin to manage their glucose levels, but Ryzodeg acts as a perfect substitute to bolus and basal insulin.
  • Ryzodeg serves the purpose of the two insulin's, making it more convenient for consumers. Due to its unique combination, the market for the drug is expected to grow exponentially shortly.
  • Ryzodeg is available in close to 18 countries, but Novo Nordisk plans to increase its marketing and sales resources to improve the availability of the drug inadvertently.

Competitive Landscape

  • The combination anti-diabetes drugs market is highly consolidated. Novo Nordisk market share is expected to increase because of the launch of Xultophy and Ryzodeg in many other countries.
  • Nov 2017: Novo Nordisk Korea has launched diabetes treatment Ryzodeg in the Korean market. Ryzodeg is the first combination insulin injection made from a 70-30 ratio of two types of insulin- insulin degludec and insulin aspart.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 BY Drug
    • 5.1.1 Combination Drugs
      • 5.1.1.1 Insulin Combinations
      • 5.1.1.1.1 NovoMix (Biphasic Insulin Aspart)
      • 5.1.1.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
      • 5.1.1.1.3 Xultophy (Insulin Degludec and Liraglutide)
      • 5.1.1.2 Oral Combination
      • 5.1.1.2.1 Janumet (Sitagliptin and Metformin HCl)
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume 2012-2024)
      • 5.2.1.2 Canada (Value and Volume 2012-2024)
      • 5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    • 5.2.2 Europe
      • 5.2.2.1 France (Value and Volume 2012-2024)
      • 5.2.2.2 Germany (Value and Volume 2012-2024)
      • 5.2.2.3 Italy (Value and Volume 2012-2024)
      • 5.2.2.4 Spain (Value and Volume 2012-2024)
      • 5.2.2.5 United Kingdom (Value and Volume 2012-2024)
      • 5.2.2.6 Russia (Value and Volume 2012-2024)
      • 5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value and Volume 2012-2024)
      • 5.2.3.2 Brazil (Value and Volume 2012-2024)
      • 5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
    • 5.2.4 Asia - Pacific
      • 5.2.4.1 Australia (Value and Volume 2012 - 2024)
      • 5.2.4.2 China (Value and Volume 2012-2024)
      • 5.2.4.3 India (Value and Volume 2012-2024)
      • 5.2.4.4 Indonesia (Value and Volume 2012-2024)
      • 5.2.4.5 Japan (Value and Volume 2012-2024)
      • 5.2.4.6 Malaysia (Value and Volume 2012-2024)
      • 5.2.4.7 Philippines (Value and Volume 2012-2024)
      • 5.2.4.8 South Korea (Value and Volume 2012-2024)
      • 5.2.4.9 Thailand (Value and Volume 2012-2024)
      • 5.2.4.10 Vietnam (Value and Volume 2012-2024)
      • 5.2.4.11 Rest of Asia - Pacific (Value and Volume 2012-2024)
    • 5.2.5 Middle East & Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
      • 5.2.5.2 Iran (Value and Volume 2012-2024)
      • 5.2.5.3 Egypt (Value and Volume 2012-2024)
      • 5.2.5.4 Oman (Value and Volume 2012-2024)
      • 5.2.5.5 South Africa (Value and Volume 2012-2024)
      • 5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes population (2012-2024)
  • 6.2 Type-2 Diabetes population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Merck
    • 7.1.3 Sanofi

8 MARKET OPPORTUNITIES AND FUTURE TRENDS